RNTX

Rein is a pre-revenue, clinical-stage biopharma whose investability is decided by the balance sheet, and that balance sheet is alarming. FY2025 cash and equivalents stand at just $3.21M (down 75% YoY) against operating cash burn of -$19.4M. That is roughly two months of runway at the current rate — the company cannot fund the RENEW Phase 2 trial it just started without raising capital imminently. Stockholders' equity collapsed 68.9% to $16.9M, total assets fell 61.2% to $24.2M, and the accumulated deficit is -$401M. Current assets ($4.33M) are below current liabilities ($6.18M), so working capital is already negative. ROE of -294.8% is meaningless except as a flag that equity is being incinerated.

The filing language confirms the squeeze rather than relieving it. Management explicitly cites 'current capital limitations,' has suspended LTI-01 and all preclinical fibrosis work 'for an indefinite period,' and is funneling everything into the single lead asset LTI-03. The company is now a one-shot bet on LTI-03 in idiopathic pulmonary fibrosis. It dosed its first RENEW patient only in March 2026 and won't report interim topline data until Q4 2026 — meaning the cash runs out long before the catalyst that could justify the stock. The shares-outstanding count already rose 27.5% YoY, and with $145.5M historically raised through stock/warrants plus an active at-the-market program, the near-certain next step is a dilutive raise at a depressed ~$1.04 price, likely with warrants. Existing holders face heavy dilution simply to keep the lights on.